Hepatitis C is a major public health concern around the world. It is estimated that approximately 3% of the world's population, or as many as 170 million persons worldwide, are infected with hepatitis C virus (HCV). 1 HCV was discovered by characterization of the viral genome in 1989, 2 without the actual isolation of the virus itself. The virus is a member of the flaviviridae family with a genome of single stranded RNA. Various genotypes exist in different regions of the world. So far, six major genotypes have been isolated with genotypes 1-3 described worldwide, genotypes 4 and 5 principally in Africa and genotype 6 primarily in Asia. 1 In Canada, the major genotypes are 1, 2, and 3. [3] [4] [5] Hepatitis C is usually a subclinical infection with only 25% of patients with posttransfusion hepatitis developing jaundice. 6 In other prospective studies, only 20-30% of the patients had symptoms and approximately half of the symptomatic group developed jaundice. 7 Clinically and histopathologically, hepatitis C is similar to viral hepatitis caused by other pathogens. 8 The most important feature of hepatitis C is the high frequency (75-85%) with which acute disease progresses to chronic infection. Available studies of hepatitis C infection have shown that the disease has a protracted course and serious sequelae may not appear until decades after initial infection. 9 The pathogenesis of and the immune response to hepatitis C are poorly understood. Infection by HCV does not seem to induce a protective humoral response but it is becoming clear that some infected individuals do recover from their infection.
Hepatitis C is transmitted through blood or body fluids contaminated with the virus. 10,11 Important risk factors associated with transmission of HCV are the sharing of drug injection equipment and the receipt of unscreened blood or blood products. Vertical and sexual transmission can also occur. Inapparent parenteral exposure such as tattooing, body piercing and sharing of personal hygiene items, only if the instruments or items for such activities are contaminated with blood or body fluids, are also presumed to be risk factors. In different countries the relative importance of risk factors can vary both regionally and temporally. For example, until recently blood transfusion was an important route of transmission; however, with the development and implementation of sensitive (and specific) screening methods, the risk associated with blood transfusion and the use of blood products has been markedly reduced. In most developed countries such risk is minimal at the present time whereas in some developing countries the risk may still be at a relatively high level. 12 As there are still many unanswered questions about HCV itself and the immune responses it induces, there is currently no vaccine developed for the disease. As a result, prevention and control rely primarily on the successful interruption of viral transmission and the management of cases. Treatment with interferon alone or combined with ribavirin has been shown to be effective in some cases, especially with the combination therapy for infections caused by certain genotypes of HCV. 13 In Canada, surveillance and studies for HCV infection have been actively carried out to assess the risk of hepatitis C, to identify the major factors affecting the transmission of HCV, and to determine effective intervention measures for control of the disease.
Public health surveillance of hepatitis C in Canada
Public health surveillance for hepatitis C in Canada consists of the reporting of identified cases, enhanced surveillance and targeted research.
By January 1999, hepatitis C became reportable in all provinces and territories across the country. To determine the current status of surveillance activities for hepatitis C in different jurisdictions, a survey of the 12 provincial and territorial epidemiologists was conducted by Laboratory Centre for Disease Control (LCDC) in 1998. According to the survey, positive laboratory testing results were the criteria to stimulate reporting, with confirmed anti-HCV in all and HCV-RNA or seroconversion in some jurisdictions. Confirmatory testing was done either in central provincial laboratories, designated hospital laboratories or the federal laboratory. Health care sectors that must report HCV infections were laboratories (10 jurisdictions), physicians (11 jurisdictions), hospitals (8 jurisdictions) and the blood services (9 jurisdictions). A database had been set up for hepatitis C in 11 jurisdictions and duplicates had been checked in all 10 jurisdictions that answered this question.
While the nationwide reporting of hepatitis is important for the surveillance of hepatitis C, the data collected from such reporting are limited due to the nature of the infection, e.g., asymptomatic in most infections, the slow progression of the dis-
